David Shaw’s enGene Therapeutics ENGN Stock Holding History
Bought
Maintained
Sold
Other funds holding ENGN
BCM
SL
ACA
David Shaw's ENGN Position: Q3 2026 in Review
David Shaw opened a new position in enGene Therapeutics (ENGN) in Q3 2026: 170,408 shares worth $341K. The stake represents ﹤0.01% of the portfolio and ranks #4431 among its holdings.
60 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.
- David Shaw held 170,408 shares of enGene Therapeutics worth $341K as of Q3 2026.
- enGene Therapeutics was a new David Shaw position in Q3 2026.
- enGene Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q3 2026, its #4431 holding.
- 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.
Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.